Marker Therapeutics Inc (MRKR)

$3.94

-0.15

(-3.62%)▲

Market is closed - opens 7 PM, 23 May 2024

Insights on Marker Therapeutics Inc

  • Increasing Revenue

    Revenue is up for the last 3 quarters, 257.60K → 1.24M (in $), with an average increase of 45.4% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 3 quarters, -2.98M → -2.39M (in $), with an average increase of 11.7% per quarter

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 232.5% return, outperforming this stock by 317.7%

Performance

  • $3.87
    $4.19
    $3.94
    downward going graph

    1.78%

    Downside

    Day's Volatility :7.64%

    Upside

    5.97%

    downward going graph
  • $1.16
    $9.68
    $3.94
    downward going graph

    70.56%

    Downside

    52 Weeks Volatility :88.02%

    Upside

    59.3%

    downward going graph

Returns

PeriodMarker Therapeutics IncIndex (Russel 2000)
3 Months
3.49%
0.0%
6 Months
52.53%
0.0%
1 Year
214.45%
0.0%
3 Years
-84.86%
-20.1%

Highlights

Market Capitalization
37.5M
Book Value
$1.33
Earnings Per Share (EPS)
-1.38
Wall Street Target Price
11.75
Profit Margin
-170.5%
Operating Margin TTM
-204.9%
Return On Assets TTM
-38.13%
Return On Equity TTM
-88.18%
Revenue TTM
3.3M
Revenue Per Share TTM
0.38
Quarterly Revenue Growth YOY
0.8%
Gross Profit TTM
-17.1M
EBITDA
-11.8M
Diluted Eps TTM
-1.38
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
0.0
EPS Estimate Next Year
-1.28
EPS Estimate Current Quarter
0.0
EPS Estimate Next Quarter
0.0

Analyst Recommendation

Buy
    85%Buy
    14%Hold
    0
    0%Sell
Based on 7 Wall street analysts offering stock ratings for Marker Therapeutics Inc(by analysts ranked 0 to 5 stars)
Based on 7 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
6
6
6
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 198.22%

Current $3.94
Target $11.75

Company Financials

FY18Y/Y Change
Revenue
206.0K
-
Net Income
-148.0M
↑ 1247.25%
Net Profit Margin
-71.8K%
-
FY19Y/Y Change
Revenue
213.2K
↑ 3.5%
Net Income
-20.3M
↓ 86.26%
Net Profit Margin
-9.5K%
↑ 62291.75%
FY20Y/Y Change
Revenue
466.8K
↑ 118.95%
Net Income
-28.5M
↑ 40.34%
Net Profit Margin
-6.1K%
↑ 3423.34%
FY21Y/Y Change
Revenue
1.2M
↑ 166.01%
Net Income
-41.9M
↑ 46.79%
Net Profit Margin
-3.4K%
↑ 2739.01%
FY22Y/Y Change
Revenue
9.0M
↑ 625.17%
Net Income
-29.9M
↓ 28.56%
Net Profit Margin
-332.23%
↑ 3039.99%
FY23Y/Y Change
Revenue
3.3M
↓ 63.23%
Net Income
-17.0M
↓ 43.28%
Net Profit Margin
-512.46%
↓ 180.23%
Q4 FY22Q/Q Change
Revenue
6.1M
↑ 105.24%
Net Income
-4.0M
↓ 41.42%
Net Profit Margin
-65.98%
↑ 165.2%
Q1 FY23Q/Q Change
Revenue
3.5M
↓ 42.19%
Net Income
-4.9M
↑ 22.24%
Net Profit Margin
-139.53%
↓ 73.55%
Q2 FY23Q/Q Change
Revenue
762.7K
↓ 78.21%
Net Income
2.5M
↓ 151.52%
Net Profit Margin
329.87%
↑ 469.4%
Q3 FY23Q/Q Change
Revenue
257.6K
↓ 66.22%
Net Income
-3.0M
↓ 218.53%
Net Profit Margin
-1.2K%
↓ 1487.44%
Q4 FY23Q/Q Change
Revenue
1.1M
↑ 310.13%
Net Income
-2.7M
↓ 8.11%
Net Profit Margin
-259.35%
↑ 898.22%
Q1 FY24Q/Q Change
Revenue
1.2M
↑ 17.75%
Net Income
-2.4M
↓ 12.67%
Net Profit Margin
-192.34%
↑ 67.01%
FY18Y/Y Change
Total Assets
62.1M
↑ 1099.6%
Total Liabilities
2.8M
↑ 84.17%
FY19Y/Y Change
Total Assets
46.4M
↓ 25.4%
Total Liabilities
2.3M
↓ 18.92%
FY20Y/Y Change
Total Assets
45.6M
↓ 1.61%
Total Liabilities
18.3M
↑ 703.77%
FY21Y/Y Change
Total Assets
68.1M
↑ 49.37%
Total Liabilities
24.1M
↑ 32.18%
FY22Y/Y Change
Total Assets
34.4M
↓ 49.48%
Total Liabilities
14.8M
↓ 38.63%
FY23Y/Y Change
Total Assets
17.1M
↓ 50.24%
Total Liabilities
3.1M
↓ 79.25%
Q4 FY22Q/Q Change
Total Assets
34.4M
↓ 16.28%
Total Liabilities
14.8M
↓ 19.94%
Q1 FY23Q/Q Change
Total Assets
27.9M
↓ 18.83%
Total Liabilities
12.0M
↓ 18.85%
Q2 FY23Q/Q Change
Total Assets
22.0M
↓ 21.42%
Total Liabilities
2.9M
↓ 75.72%
Q3 FY23Q/Q Change
Total Assets
19.5M
↓ 11.25%
Total Liabilities
2.8M
↓ 4.84%
Q4 FY23Q/Q Change
Total Assets
17.1M
↓ 12.11%
Total Liabilities
3.1M
↑ 10.63%
Q1 FY24Q/Q Change
Total Assets
14.1M
↓ 17.72%
Total Liabilities
2.3M
↓ 25.08%
FY18Y/Y Change
Operating Cash Flow
-14.5M
↑ 71.57%
Investing Cash Flow
-147.7K
↑ 0.0%
Financing Cash Flow
71.2M
↑ 1146.09%
FY19Y/Y Change
Operating Cash Flow
-18.3M
↑ 26.27%
Investing Cash Flow
-375.0K
↑ 153.94%
Financing Cash Flow
816.5K
↓ 98.85%
FY20Y/Y Change
Operating Cash Flow
-18.9M
↑ 3.15%
Investing Cash Flow
-10.4M
↑ 2680.91%
Financing Cash Flow
6.7M
↑ 725.01%
FY21Y/Y Change
Operating Cash Flow
-27.3M
↑ 44.65%
Investing Cash Flow
-3.1M
↓ 69.97%
Financing Cash Flow
52.6M
↑ 680.22%
Q4 FY22Q/Q Change
Operating Cash Flow
-6.3M
↓ 17.53%
Investing Cash Flow
-112.6K
↑ 13.33%
Financing Cash Flow
138.6K
↓ 221.95%
Q1 FY23Q/Q Change
Operating Cash Flow
-5.9M
↓ 6.62%
Investing Cash Flow
-112.6K
↑ 0.0%
Financing Cash Flow
620.0K
↑ 347.45%

Technicals Summary

Sell

Neutral

Buy

Marker Therapeutics Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Marker Therapeutics Inc
Marker Therapeutics Inc
-2.44%
52.53%
214.45%
-84.86%
-92.85%
Moderna, Inc.
Moderna, Inc.
37.56%
83.82%
13.37%
-12.47%
553.14%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
10.42%
24.29%
32.26%
98.6%
210.52%
Novo Nordisk A/s
Novo Nordisk A/s
7.9%
30.89%
58.53%
230.87%
458.51%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
10.52%
25.13%
30.01%
109.26%
156.43%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Marker Therapeutics Inc
Marker Therapeutics Inc
NA
NA
NA
0.0
-0.88
-0.38
NA
1.33
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-6.46
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
29.16
29.16
1.46
44.2
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
45.83
45.83
2.36
3.5
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
28.9
28.9
0.53
17.11
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Marker Therapeutics Inc
Marker Therapeutics Inc
Buy
$37.5M
-92.85%
NA
-170.5%
Moderna, Inc.
Moderna, Inc.
Buy
$54.0B
553.14%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$108.8B
210.52%
29.16
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$592.1B
458.51%
45.83
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$115.1B
156.43%
28.9
39.46%

Institutional Holdings

  • NEA Management Company, LLC

    12.02%

  • Aisling Capital Management LP

    3.53%

  • Vanguard Group Inc

    2.62%

  • Wedbush Morgan Securities Inc

    0.78%

  • Geode Capital Management, LLC

    0.67%

  • Northern Trust Corp

    0.43%

Company Information

tapimmune is developing immunotherapies for a variety of cancers designed to target both tumors and metastatic disease. the company’s next-generation technology has been engineered to overcome the deficiencies of earlier cancer vaccine approaches and has the potential to be a powerful standalone therapy or part of a leading combination regimen by complementing other approved or development-stage immunotherapeutics (i.e. checkpoint inhibitors). the company’s off-the-shelf vaccines boost patients’ immune systems to comprehensively stimulate both killer t-cells and helper t-cells to destroy cancer cells, and they are designed to work with 80% of the population. tapimmune is advancing two clinical stage t-cell vaccine candidates in multiple phase ii and phase ib/iia clinical trials for treating ovarian and breast cancers, including programs in ovarian cancer that will benefit from fda fast track and orphan disease designation. the company is working in collaboration with industry and clini

Organization
Marker Therapeutics Inc
Employees
8
CEO
Dr. Juan F. Vera M.D.
Industry
Consumer Services

Discover More

FAQs